Accession Number : ADA476862


Title :   Assessment of a DNA Vaccine Encoding Burkholderia pseudomallei Bacterioferritin


Descriptive Note : Technical rept.


Corporate Author : DEFENCE SCIENCE AND TECHNOLOGY ORGANISATION VICTORIA (AUSTRALIA) HUMAN PROTECTION AND PERFORMANCE DIV


Personal Author(s) : McAllister, Jane ; Gauci, Penny ; Lazzaroni, Sharon ; Barnes, Jodie ; Ketheesan, Natkunam ; Proll, David


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA476862


Report Date : AUG 2007


Pagination or Media Count : 24


Abstract : Burkholderia pseudomallei is the causative agent of melioidosis, a disease endemic in Southeast Asia and Northern Australia. The bacteria cause infection via subcutaneous or inhaled routes, resulting in either acute lethal sepsis or chronic and eventually fatal disease. Currently no licensed vaccine is available to provide protection against this pathogen. Intracellular enzymatic proteins of other bacterial species, such as the iron storage protein bacterioferritin, have been shown to be potent inducers of the immune response. In this study, a DNA vaccine encoding the B. pseudomallei bacterioferritin protein was constructed. The DNA vaccine was then used to immunise mice and analyse subsequent immune responses and protective capability following live challenge with B. pseudomallei. There was a substantial increase in anti-bacterioferritin IgG titers following immunisation, however the cellular response and survival following challenge was limited, suggesting that the vaccine may need to be used in conjunction with adjuvant such as CpG or in a multicomponent vaccine in order to increase protective capabilities.


Descriptors :   *BACTERIA , *DEOXYRIBONUCLEIC ACIDS , *IMMUNITY , *INFECTIOUS DISEASES , *CELLS(BIOLOGY) , *PSEUDOMONADALES , ENZYMES , CODING , NORTH(DIRECTION) , SOUTHEAST ASIA , MELIOIDOSIS , SEPSIS , VACCINES , STORAGE , AUSTRALIA , MICE , RESPONSE(BIOLOGY) , LETHALITY , IRON , PROTEINS


Subject Categories : BIOCHEMISRTY
      MEDICINE AND MEDICAL RESEARCH
      MICROBIOLOGY


Distribution Statement : APPROVED FOR PUBLIC RELEASE